606 related articles for article (PubMed ID: 33859638)
41. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Selman-Housein Bernal KH; de la Torre Santos A; Santiesteban Álvarez ER; Martín Bauta Y; Bermúdez Badell CH; de la Torre Pupo J; Gavilondo JV; ; Ayala Avila M
BMC Immunol; 2017 Jul; 18(1):39. PubMed ID: 28747172
[TBL] [Abstract][Full Text] [Related]
42. Peptide vaccines for cancer therapy.
Cerezo D; Peña MJ; Mijares M; Martínez G; Blanca I; De Sanctis JB
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(1):38-45. PubMed ID: 25642777
[TBL] [Abstract][Full Text] [Related]
43. Cancer vaccines: between the idea and the reality.
Finn OJ
Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
[TBL] [Abstract][Full Text] [Related]
44. Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy.
Duong HTT; Yin Y; Thambi T; Nguyen TL; Giang Phan VH; Lee MS; Lee JE; Kim J; Jeong JH; Lee DS
Biomaterials; 2018 Dec; 185():13-24. PubMed ID: 30216806
[TBL] [Abstract][Full Text] [Related]
45. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
46. Cancer vaccines.
Muehlbauer PM; Schwartzentruber DJ
Semin Oncol Nurs; 2003 Aug; 19(3):206-16. PubMed ID: 12962010
[TBL] [Abstract][Full Text] [Related]
47. Current status of DNA vaccines and their route of administration.
Alpar HO; Bramwell VW
Crit Rev Ther Drug Carrier Syst; 2002; 19(4-5):307-83. PubMed ID: 12661697
[TBL] [Abstract][Full Text] [Related]
48. Microparticles as vaccine adjuvants and delivery systems.
O'Hagan DT; Singh M
Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
[TBL] [Abstract][Full Text] [Related]
49. Personalized cancer vaccines: Targeting the cancer mutanome.
Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
[TBL] [Abstract][Full Text] [Related]
50. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
Jin Z; Gao S; Cui X; Sun D; Zhao K
Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
[TBL] [Abstract][Full Text] [Related]
51. Live-attenuated Listeria-based immunotherapy.
Rothman J; Paterson Y
Expert Rev Vaccines; 2013 May; 12(5):493-504. PubMed ID: 23659298
[TBL] [Abstract][Full Text] [Related]
52. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
53. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression.
Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161
[TBL] [Abstract][Full Text] [Related]
54. At the bench: Engineering the next generation of cancer vaccines.
Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
[TBL] [Abstract][Full Text] [Related]
55. Cancer vaccines.
Bonnefoy JY
Expert Opin Ther Targets; 2004 Dec; 8(6):521-5. PubMed ID: 15584859
[TBL] [Abstract][Full Text] [Related]
56. Protein-based nanoparticles in cancer vaccine development.
Neek M; Kim TI; Wang SW
Nanomedicine; 2019 Jan; 15(1):164-174. PubMed ID: 30291897
[TBL] [Abstract][Full Text] [Related]
57. Microparticles and nanoparticles as delivery systems for DNA vaccines.
Cui Z; Mumper RJ
Crit Rev Ther Drug Carrier Syst; 2003; 20(2-3):103-37. PubMed ID: 14584521
[TBL] [Abstract][Full Text] [Related]
58. Production of Adjuvant-Loaded Biodegradable Particles for Use in Cancer Vaccines.
de Barros CM; Wafa EI; Chitphet K; Ahmed K; Geary SM; Salem AK
Methods Mol Biol; 2017; 1494():201-213. PubMed ID: 27718195
[TBL] [Abstract][Full Text] [Related]
59. Lipid-based mRNA vaccine delivery systems.
Midoux P; Pichon C
Expert Rev Vaccines; 2015 Feb; 14(2):221-34. PubMed ID: 25540984
[TBL] [Abstract][Full Text] [Related]
60. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
Banday AH; Jeelani S; Hruby VJ
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
